BioSpace News Archive

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced the launch of its second generation CleanFlow™ Procedure Instrument.

Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies for CNS and eye diseases, announces that CEO Rodolphe Clerval will be presenting to investors and peers at the following Investor and Industry conferences:

Cell-Easy, a specialized contract development and manufacturing organization in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre as the Chief Scientific Officer.

Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego.

Harpoon Therapeutics, Inc. announced the presentation of interim data for the 2.15 to 12 mg target dose cohorts from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma.

Orange Grove Bio announced that Preservation Bio, one of the firm’s majority-owned subsidiaries, has been awarded a $2.05 million Small Business Innovation Research direct-to-Phase II grant by the National Heart, Lung, and Blood Institute, one of 27 institutes under the National Institutes of Health umbrella.

Bio-Techne Corporation announced that Dr. Jordan Laser has received the AMP Meritorious Service Award from the Association for Molecular Pathology.

Partners STADA and Calliditas Therapeutics AB announced the submission of a request to the European Medicines Agency for the Committee for Medicinal Products for Human Use to convert the conditional marketing authorization for Kinpeygo®, their treatment for primary IgA nephropathy, to standard, or “full”, marketing authorization.

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held from October 1 - 4, 2023, in Toronto, Canada.

Renalytix plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023.